AVAVA, Inc. announced a $35 million funding has been secured for its focus on advancing image-guided intradermal laser products that are safe and effective for all skin tones.
The financing will allow AVAVA to move forward in developing products and reach expansion goals already approved by the board of directors.
“This financing represents an important moment in AVAVA’s journey as we move forward in our mission to revolutionize the aesthetics industry,” said Dr. Irina Erenburg, CEO of AVAVA. “We are excited to continue our expansion plans and advance the next generation of products in our pipeline, while delivering best-in-class treatments for individual needs.”
The funding will accelerate the commercialization of its main product, MIRIA.
MIRIA is the first of a new class of aesthetic dermatology lasers utilizing proprietary Focal Point Technology to deliver energy with pinpoint accuracy anywhere in the skin. AVAVA says this enhances skin revitalization outcomes for patients of all skin tones.
AVAVA recently completed its Series C round, which raised $25 million in funding from new and existing investors, including strategic partner Jeisys Medical, INC. The company also secured $10 million in growth capital from Catalio Capital Management, LP, a leading multi-strategy investment firm focused on healthcare and life sciences.
“As a leading investor in cutting-edge healthcare technologies, Catalio is thrilled to partner with AVAVA as the company continues to make remarkable progress,” said Jonathan Blankfein, Partner & Portfolio Manager at Catalio Capital Management. “This investment further demonstrates our firm’s commitment to working with disruptive and innovative companies not just as an investor, but as a long-term strategic partner.”
